vs
Side-by-side financial comparison of MODIV INDUSTRIAL, INC. (MDV) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $11.1M, roughly 1.7× MODIV INDUSTRIAL, INC.). SCYNEXIS INC runs the higher net margin — 65.7% vs 11.0%, a 54.8% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -5.6%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -3.8%).
MODIV INDUSTRIAL, INC. is a U.S.-based industrial real estate enterprise focused on acquiring, owning and operating high-quality industrial properties mainly located in key logistics and distribution hubs across North America. It serves tenants from sectors including e-commerce fulfillment, manufacturing and third-party logistics, addressing rising demand for modern supply chain infrastructure.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
MDV vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.1M | $18.6M |
| Net Profit | $1.2M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 45.8% | 56.3% |
| Net Margin | 11.0% | 65.7% |
| Revenue YoY | -5.6% | 1808.5% |
| Net Profit YoY | -22.0% | 376.5% |
| EPS (diluted) | $0.02 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.1M | $18.6M | ||
| Q3 25 | $11.7M | $334.0K | ||
| Q2 25 | $11.8M | $1.4M | ||
| Q1 25 | $11.8M | $257.0K | ||
| Q4 24 | $11.7M | $977.0K | ||
| Q3 24 | $11.7M | $660.0K | ||
| Q2 24 | $11.4M | $736.0K | ||
| Q1 24 | $12.0M | $1.4M |
| Q4 25 | $1.2M | $12.3M | ||
| Q3 25 | $1.0M | $-8.6M | ||
| Q2 25 | $-2.0M | $-6.9M | ||
| Q1 25 | $829.0K | $-5.4M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $-587.0K | $-2.8M | ||
| Q2 24 | $1.3M | $-14.5M | ||
| Q1 24 | $3.7M | $411.0K |
| Q4 25 | 45.8% | 56.3% | ||
| Q3 25 | 41.4% | -2516.5% | ||
| Q2 25 | 9.8% | -701.0% | ||
| Q1 25 | 40.2% | -3350.2% | ||
| Q4 24 | 45.4% | — | ||
| Q3 24 | 42.0% | -1563.6% | ||
| Q2 24 | 44.6% | -1255.0% | ||
| Q1 24 | 55.6% | -692.5% |
| Q4 25 | 11.0% | 65.7% | ||
| Q3 25 | 9.0% | -2572.2% | ||
| Q2 25 | -17.1% | -504.8% | ||
| Q1 25 | 7.0% | -2097.7% | ||
| Q4 24 | 13.3% | — | ||
| Q3 24 | -5.0% | -425.5% | ||
| Q2 24 | 11.6% | -1964.4% | ||
| Q1 24 | 31.1% | 29.9% |
| Q4 25 | $0.02 | $0.25 | ||
| Q3 25 | $0.00 | $-0.17 | ||
| Q2 25 | $-0.32 | $-0.14 | ||
| Q1 25 | $-0.01 | $-0.11 | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $-0.18 | $-0.06 | ||
| Q2 24 | $0.03 | $-0.30 | ||
| Q1 24 | $0.33 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.4M | $40.0M |
| Total DebtLower is stronger | $261.5M | — |
| Stockholders' EquityBook value | $162.7M | $49.4M |
| Total Assets | $476.5M | $59.0M |
| Debt / EquityLower = less leverage | 1.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $40.0M | ||
| Q3 25 | $8.3M | $37.9M | ||
| Q2 25 | $5.8M | $44.8M | ||
| Q1 25 | $6.2M | $40.6M | ||
| Q4 24 | $11.5M | $59.3M | ||
| Q3 24 | $6.8M | $68.8M | ||
| Q2 24 | $18.9M | $73.0M | ||
| Q1 24 | $18.4M | $80.2M |
| Q4 25 | $261.5M | — | ||
| Q3 25 | $279.7M | — | ||
| Q2 25 | $279.7M | — | ||
| Q1 25 | $279.7M | — | ||
| Q4 24 | $279.8M | — | ||
| Q3 24 | $279.7M | — | ||
| Q2 24 | $279.7M | — | ||
| Q1 24 | $279.6M | — |
| Q4 25 | $162.7M | $49.4M | ||
| Q3 25 | $164.8M | $36.4M | ||
| Q2 25 | $165.6M | $44.5M | ||
| Q1 25 | $171.1M | $50.5M | ||
| Q4 24 | $190.1M | $55.1M | ||
| Q3 24 | $186.3M | $58.5M | ||
| Q2 24 | $187.0M | $60.4M | ||
| Q1 24 | $188.0M | $74.1M |
| Q4 25 | $476.5M | $59.0M | ||
| Q3 25 | $499.6M | $51.1M | ||
| Q2 25 | $498.9M | $60.7M | ||
| Q1 25 | $506.8M | $67.9M | ||
| Q4 24 | $507.8M | $90.6M | ||
| Q3 24 | $507.4M | $99.0M | ||
| Q2 24 | $519.5M | $107.8M | ||
| Q1 24 | $522.5M | $118.3M |
| Q4 25 | 1.61× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.69× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 1.50× | — | ||
| Q2 24 | 1.50× | — | ||
| Q1 24 | 1.49× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.0M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 12.34× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.0M | $18.4M | ||
| Q3 25 | $4.1M | $-8.7M | ||
| Q2 25 | $3.9M | $-7.5M | ||
| Q1 25 | $3.0M | $-7.5M | ||
| Q4 24 | $18.2M | $-24.0M | ||
| Q3 24 | $5.1M | $765.0K | ||
| Q2 24 | $4.7M | $-10.9M | ||
| Q1 24 | $3.0M | $-4.0M |
| Q4 25 | 12.34× | 1.50× | ||
| Q3 25 | 3.95× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.68× | — | ||
| Q4 24 | 11.72× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.55× | — | ||
| Q1 24 | 0.80× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MDV
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
